Jiangxi

我们是谁

• 1 月 9, 2024

  A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator’s Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) ( CheckMate 8HW )

• 10 月 31, 2023

  Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC

• 4 月 5, 2022

  KRAS G12C突变晚期结直肠癌患者MRTX849联合西妥昔单抗与化疗的3期研究（KRYSTAL-10）